Polpharma BiologicsS.A.
Research and experimental development in natural sciences and engineering
Overview
Polpharma Biologics is a biotechnology company that specializes in the development and manufacturing of biosimilars and innovative biologics. They provide customized CDMO services, taking biosimilars from concept to clinical trials and supporting global commercial supply. The company collaborates with major biopharmaceutical partners to enhance patient access to high-quality alternatives for various diseases.
Financials
Revenue history (in m)
Data and insights are generated automatically based on financial statements and may contain errors. This analysis is for informational purposes only and does not constitute an official assessment of the company's credibility or business advice.
Statistics
How the company ranks by revenue within its industry, region and across Poland in 2025.
Results vs industry
News
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate
Rotkreuz – 31 July 2026 – Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately…
Teva and Polpharma Biologics Announce Global Licensing Agreement for A Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
TEL AVIV, ISRAEL, and Zug, Switzerland July 9, 2026 (GLOBE NEWSWIRE) – Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE: and TASE: TEVA) and Polpharma Biologics International AG today announced a global licensing agreement granting Teva exclusive rights to commercialize both formulations of Polpharma Biologics’ proposed biosimilar to Ocrevus® 1 (ocrelizumab), upon regulatory approval. This strategic agreement is expected to combine Polpharma…
Polpharma Biologics and PSI CRO Collaborate on Phase 1 Biosimilar Study in Multiple Sclerosis
June 03, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development of biosimilars, announced a collaboration with PSI CRO for the execution of a Phase 1 clinical study evaluating PB018, a proposed biosimilar to Ocrevus® (ocrelizumab), in patients with Multiple Sclerosis (MS).
Polpharma Biologics and Tuteur sign a licensing agreement for a biosimilar targeting autoimmune diseases
May 22, 2026 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur . Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil. Polpharma Biologics will retain full responsibility for the development and manufacturing of the…
Bioeq and Zydus partners for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO® BLA has been approved by the USFDA
December 23, 2025 –Polpharma Biologics is pleased to acknowledge the recent announcement of Bioeq AG, our joint venture, regarding the licensing, supply, and commercialization agreement with Zydus Lifesciences Ltd. for NUFYMCO® (biosimilar ranibizumab), an interchangeable biosimilar to Lucentis®, in the United States.
Polpharma Biologics and Libbs Farmacêutica sign licensing agreement for a biosimilar for autoimmune diseases
December 10, 2025 – Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, is thrilled to announce the signing of a landmark licensing agreement with the Brazilian company Libbs Farmacêutica! Through this strategic partnership, Libbs Farmacêutica will gain exclusive rights to commercialize a cutting-edge biosimilar for autoimmune diseases in the rapidly growing Brazilian market.
Industry
Bank accounts
Registered as a VAT taxpayer on 2019-01-09. Active
53 1030 1016 0000 0000 9301 4401- 10 1030 1016 0000 0000 9301 4496
- 80 1030 1016 0000 0000 9301 4497
Debt
No entries in the National Debtors Register (KRZ). No proceedings in KRZ
MSiG notices
| Publication date | Event | |
|---|---|---|
| Oct 1, 2026 | Call to creditors | |
| Apr 29, 2026 | Call to creditors |
Public aid
10 public aid cases recorded, with a total value of $41,268,401.
| Grant date | Purpose | Gross amount | Granting body | |
|---|---|---|---|---|
| Jun 29, 2026 | Aid for research and development projects: experimental development | —— | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 26, 2026 | Aid for research and development projects: experimental development | —— | Dyrektor Narodowego Centrum Badań i Rozwoju | |
| Jun 26, 2026 | Aid for research and development projects: industrial research | —— | Dyrektor Narodowego Centrum Badań i Rozwoju |
European Funds
8 projects co-financed from European Funds recorded, with total EU co-financing of $57,379,029.
| Start | Project | EU co-financing | Programme | |
|---|---|---|---|---|
| 2026-01-01 | Strategiczne wzmocnienie UE w zakresie leków biologicznych poprzez rozwój nowoczesnego centrum produkcji substancji leczniczych | $4.6M$4,577,050 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2025-09-01 | Opracowanie nowego, wydajnego procesu wytwarzania biopodobnego przeciwciała monoklonalnego stosowanego w leczeniu chorób autoimmunologicznych | $5.2M$5,206,755 | Fundusze Europejskie dla Nowoczesnej Gospodarki | |
| 2025-09-01 | Opracowanie sposobu wytwarzania i charakterystyki enzymu o strategicznym znaczeniu dla produkcji leków | $4.0M$4,006,874 | Fundusze Europejskie dla Nowoczesnej Gospodarki |
Tenders
No recorded participation in tenders.
Regulatory authorisations
| Authority | Type | Status | |
|---|---|---|---|
 BDO | Integrated permit | Active | |
| BDO | Waste generation | Active |
Authorized Representatives
Manner of representation
If the management board is a one-person management board, the sole member of the management board is authorized to submit declarations of will on behalf of the company. If the management board is a multi-member management board, joint action by two members of the management board is required to submit declarations of will on behalf of the company.
Supervisory board
Ownership
| Owner |
|---|
Polpharma Biologics Group B.v. |
Beneficial owners
| Person | Rights | |
|---|---|---|
Jerzy Andrzej, Stanisław Starak (79)  | Za pośrednictwem innych spółek |
Competitors
| Name | Revenue | Website | ||
|---|---|---|---|---|
| SelvitaS.A. | $91,529,633.35 | selvita.com | ||
| KCRS.A. | $43,596,034.97 | kcrcro.com | ||
| InventionbioS.A. | $17,762,977.76 | inventionbio.pl | ||
| ArdigenS.A. | $12,513,309.89 | ardigen.com | ||
| GenomedS.A. | $7,373,750.46 | genomed.pl | ||
| Sidlysp. z o.o. | $4,977,649.42 | sidly.eu | ||
| Scope FluidicsS.A. | $4,660,220.99 | scopefluidics.com | ||
| MedappS.A. | $3,351,163.61 | medapp.pl | ||
| BiotechnaS.A. | $2,472,888.07 | bsbiotechna.com | ||
| Clinchoicesp. z o.o. | $2,048,208.30 | clinchoice.com |
Change history
| Date | Event | |
|---|---|---|
| 2026-09-24 | Share capital change (1,833,478,300.00 PLN → 1,175,432,600.00 PLN) | |
| 2026-04-17 | PKD change (Added: 52.10.B) | |
| 2025-12-03 | Share capital change (2,013,478,300.00 PLN → 1,833,478,300.00 PLN) | |
| 2025-09-26 | Share capital change (1,863,478,300.00 PLN → 2,013,478,300.00 PLN) | |
| 2025-07-16 | Share capital change (1,713,478,300.00 PLN → 1,863,478,300.00 PLN) |
FAQ
Last updated: 2026-09-24